Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-25-000136
Filing Date
2025-06-05
Accepted
2025-06-05 16:23:08
Documents
1
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1749154932.html 4  
1 FORM 4 wk-form4_1749154932.xml 4 8637
  Complete submission text file 0001714899-25-000136.txt   10073
Mailing Address 1 DNA WAY SOUTH SAN FRANCISCO CA 94080
Business Address
Tessier-Lavigne Marc (Reporting) CIK: 0001437435 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 251027439

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)